Log In

 
Company : Biocon Limited 
Saturday, November 12, 2016 10:00AM IST (4:30AM GMT)
 
(BSE:532523)(NSE:BIOCON)
Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India
Strengthens its 'Winning with Diabetes' Program by Collaborating with Semora's 'Diabetic Food Trail®', A Special Initiative Aimed at the Culinary World
 
Bengaluru, Karnataka, India

Biocon Ltd., Asia's premier biopharmaceuticals enterprise and the largest Indian insulins company, has collaborated with healthcare specialists for a month long patient centric support program to enable nationwide Diabetes Awareness Campaigns, Patient Education programs, and Nutrition Management programs to mark the ‘World Diabetes Day’ on Nov 14, 2016.
 
As a compassionate, caring and responsible company, Biocon’s efforts through its Winning with Diabetes program are aimed at creating awareness on diabetes management and sensitizing people on life style modification for leading a healthier and happier life. Through this month-long initiative being delivered in collaboration with 400 healthcare specialists in over 85 cities across the country, the Company is targeting to reach out to over 50,000 people.   
 
In another initiative aimed at increasing public awareness on the dietary aspect of diabetes management, Biocon’s Metabolics division has collaborated with ‘Semora Entertainment’ for a nationwide program - The Diabetic Food Trail® (DFT). This program is aimed at sensitizing the culinary industry on the importance of diabetes friendly food. In collaboration with certified nutritionists and Chefs, special diabetes friendly menus will be introduced at over 200 restaurants across the five cities of Delhi, Mumbai, Pune, Bengaluru and Chennai from Nov 12 - 30, 2016.
 
In the second edition of DFT, ‘Diabetic Masterclass’ and ‘Diabetic Fitness Bootcamps’ will also be organized. Diabetic Masterclasses will help individuals understand the nutritional values of various ingredients, read packaging labels, and learn exciting recipes so that people with diabetes can improve their dietary habits and lead a better quality of life.
 
Partha Roy Chowdhury, Head - Metabolics Division, Branded Formulations, Biocon said, “India currently has over 7 crore people with diabetes, making it the second largest population in the world, and this number is expected to cross the 10 crore mark by 2030. What is more alarming is that poor eating habits, lack of exercise and stress are driving a large number of young people towards pre-diabetes and diabetes. As a compassionate, caring and responsible company, Biocon is bringing together various stakeholders, through technology and traditional means, in this fight against diabetes. Through our ‘Winning with Diabetes’ program, we aim to empower people with diabetes with the tools to better manage their disease and improve their quality of life.”
 
Diabetes is a global epidemic, currently affecting an estimated 422 million people worldwide*. India is among the top three countries in the number of people with diabetes#, a disease that imposes a huge economic burden on patients which gets magnified further as it can lead to several related complications of the heart, kidneys, eyes and feet.

Biocon had introduced India’s first indigenously developed rh- Insulin in India in 2004 and for over  a decade, has been addressing the large need for affordable Insulin therapy in India and overseas  through its generic rh-Insulin, analogs and easy to use devices.
 
*Source: WHO
# Source: Lancet

 
About Biocon
 
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 120 countries, it is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. For more information, Visit: www.biocon.com   

 
For News Release background on Biocon Limited click here
 
Media Contact Details
Seema Ahuja, VP & Global Head, Corporate Communications, Biocon Limited, +91-9972317792, +91 (80) 28082222, seema.ahuja@biocon.com
Chidananda BA, Deputy Manager, Corporate Communications, Biocon Limited, +91-8970935708, +91 (80) 28082221, chidananda.ba@biocon.com
 
 
Submit your press release
More News from Biocon Limited

27/04/2017 9:45PM Document

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; Board of Directors Recommends 2:1 Bonus Shares

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today its consolidated financial results for the fourth quarter and full year FY17.

16/02/2017 7:25PM

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan’s Biologics License Application (BLA) for MYL-1401H, a ...

25/01/2017 8:34AM

Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today that the Ministry of Health (MoH), Malaysia, has awarded a three-year contract, to its subsidiary, Biocon ...

Similar News

20/07/2017 5:10PM

Savor a Unique Gastronomic Experience at World Food India's Food Street

Food Street at World Food India, has been curated not just to get your taste-buds kicking but also to trigger your other four senses.

No Image

20/07/2017 4:43PM Image

JMD Medico on its Aggressive Pan-India Expansion

JMD Medico Service Ltd. (a subsidiary of JMD Ventures Ltd, which is listed on BSE) announces aggressive pan India expansion plans by launching a wide range of Ayurvedic products. JMD Medico is an Ayurveda company ...